Slide 1: Compass Pathways Phase 3 COMP006 data review
© Compass Pathways | 1 Compass Pathways Phase 3 COMP006 data review July 7, 2026
Slide 2: Cautionary Note Regarding Forward-Looking Statements
© Compass Pathways | 2 Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “bel
Slide 3: Welcome
© Compass Pathways | 3 Welcome Kabir Nath Chief Executive Officer Guy Goodwin, MD Chief Medical Officer Lori Englebert Chief Commercial Officer
Slide 4: Significant Progress Towards Potential Approval of COMP360 in TRD
© Compass Pathways | 4 Significant Progress Towards Potential Approval of COMP360 in TRD Consistent Results across two highly statistically significant positive Phase 3 trials • COMP006 and COMP005 26-week data demonstrate rapid onset and remarkable durability through at least 6 months further val
Slide 5: COMP360: Transforming Mental Health Care
© Compass Pathways | 5 COMP360: Transforming Mental Health Care 1. Expectation based on Compass estimates and current market conditions 2. Wing V, et al. Poster S97 Contemporary Estimate of the National Prevalence of Treatment-Resistant Depression in the United States. J Mood Anxiety Disord. Present
Slide 6: COMP006 Clinical Data
© Compass Pathways | 6 COMP006 Clinical Data
Slide 7: Phase 3 Program in TRD: Trial Designs
© Compass Pathways | 7 Phase 3 Program in TRD: Trial Designs COMP 005 single dose N=258 COMP360 25 mg N=171 COMP 006 multiple dose N=581 COMP360 25 mg N=296 COMP360 1 mg N=143 COMP360 25 mg COMP360 1 mg COMP360 10 mg N=142 COMP360 10 mg Week 3 Week 6 Primary endpoint achieved1 P<0.001 option for ret
Slide 8: Remarkable Consistency in COMP005 & COMP006 Through 26 Weeks
© Compass Pathways | 8 Remarkable Consistency in COMP005 & COMP006 Through 6 Months* Confirms validity, consistency and durability of efficacy signal over 26 weeks Clear benefit of additional dose, either as fixed dose after 3 weeks (006) or later in 10-14 week timeframe (005) Convincing separation
Slide 9: COMP006 Enrolled a Highly Chronic TRD Population
© Compass Pathways | 9 COMP006 Enrolled a Highly Chronic TRD Population COMP36 0 1 mg (N=143) COMP360 10 mg (N=142) COMP360 25 mg (N=296) Length of current depressive episode 38.4 (45.0)37.7 (38.8)45.5 (42.7)Mean Months (SD) 30 (21.0)37 (26.1)53 (17.9)< 1 year 41 (28.7)35 (24.6)73 (24.7)1-2 years 72
Slide 10: Duration of Current Episode Strongest Predictor of Non-Response in TRD
© Compass Pathways | 10 Duration of Current Episode Strongest Predictor of Non-Response in TRD Source: European Neuropsychopharmacology. Volume 98, September 2025, Pages 26-34 (https://www.sciencedirect.com/science/article/pii/S0924977X25001294)
Slide 11: Participant Baseline Demographics in Line with Known TRD Epidemiology
© Compass Pathways | 11 Participant Baseline Demographics in Line with Known TRD Epidemiology COMP360 1 mg (N=143) COMP360 10 mg (N=142) COMP360 25 mg (N=296)COMP006 69 (48.3)68 (47.9)160 (54.1)Female, n (%) Race, n (%) 129 (90.2)123 (86.6)255 (86.1)White 6 (4.2)6 (4.2)14 (4.7)Asian 4 (2.8)3 (2.1)8
Slide 12: COMP006 - Rapid Onset and Sustained Durability to Week 26
© Compass Pathways | 12 COMP006 - Rapid Onset and Sustained Durability to Week 26 Source: Post Hoc (Include Number) Note: : CI = Confidence Interval; LSM = Least Squares Mean; MADRS = Montgomery–Åsberg Depression Rating Scale. *retreatment based on pre-specified criteria and receive either what they
Slide 13: COMP006 - COMP360 Response Can Be Rapid and Durable
© Compass Pathways | 13 Definitions (n at Week 6): Remitters (n=48) = MADRS ≤12 and no single item ≥4 Responders and Partial Responders (n=68) = % CFB in MADRS ≥ 25% and do not meet remission criterion Non-Responder (n=153) = % CFB in MADRS ≤ 25% COMP006 - COMP360 Response Can Be Rapid and Durable –
Slide 14: COMP006 - Majority of AEs Transient and Occurred on Day of Administration
© Compass Pathways | 14 COMP006 - Majority of AEs Transient and Occurred on Day of Administration MedDRA = Medical Dictionary for Regulatory Activities; N=number of participants in the treatment group in the Safety Analysis Set by administration; n = number of participants. *Illusion and Perceptual
Slide 15: COMP006 - SAEs Similar in 25mg and 1mg Arms and Low in Number Overall
© Compass Pathways | 15 COMP006 - SAEs Similar in 25mg and 1mg Arms and Low in Number Overall COMP360 1 mg COMP360 10 mg COMP360 25 mgMedDRA TEAE Preferred Term N=143N=142N=296 n (%) n (%) n (%) 9 (6.3)5 (3.5)17 (5.7)Any TESAE 4 (2.8)2 (1.4)4 (1.4)Suicidal ideation 1 (0.7)00Suicidal behaviour 001 (0
Slide 16: COMP360 Generally Well-Tolerated with Safe Profile
© Compass Pathways | 16 COMP360 Generally Well-Tolerated with Safe Profile COMP360 generally safe and well-tolerated • Majority of AEs transient and occurring on day of administration Safety data consistent with known profile of COMP360 psilocybin • No new safety signals identified SAEs simila
Slide 17: Commercial Update
© Compass Pathways | 17 Commercial Update
Slide 18: Epidemiology of TRD
© Compass Pathways | 18 ~23M ~4M ~12M Generally accepted definition of TRD: MDD patients failed by ≥ 2 antidepressant regimens of adequate dose, duration, and adherence in the same depressive episode2 TRD MDD Prevalence of US adults experiencing MDD each year1 MDD- treated patients Adult patients wh
Slide 19: TRD is Associated with a Greater Burden Compared to MDD
© Compass Pathways | 19 TRD is Associated with a Greater Burden Compared to MDD Higher comorbidity burden2 61% vs 36% experience pain* Longer depressive episodes6 49% 45% 18% 65% Remission Rate Relapse Rate < 2 ADTs ≥2 ADTs 42% 31% 13% 53% Remission Rate Relapse Rate < 2 ADTs ≥2 ADTs STAR*D Study (2
Slide 20: Emerging Profile of COMP360 has Potential to Revolutionize Mental Health Treatment
© Compass Pathways | 20 Emerging Profile of COMP360 has Potential to Revolutionize how Mental Health Conditions are Treated * Durability data across the two phase 3 programs (COMP005 and COMP006) Based on clinical trial results to date; Label has not been determined as COMP360 is not yet approved by
Slide 21: Anticipated Timeline to COMP360 Launch, if FDA Approved
© Compass Pathways | 21 Anticipated Timeline to COMP360 Launch, if FDA Approved Breakthrough Therapy designation granted by the FDA FDA rolling review and National Priority Voucher granted Anticipated completion of rolling NDA submission Anticipated launch, if FDA approved Key: FDA, Food and Drug Ad
Slide 22: Interventional Psychiatry Treatment Centers Preparing to Offer COMP360
© Compass Pathways | 22 Dedicated rooms/areas for treatments that require multi-hour monitoring Operational and scheduling capabilities with team-based workforce Scaling to meet patient demand At approval, our top priority is site and patient experience: • Training & education • REMS certification •
Slide 23: COMP360: Transforming Mental Health Care
© Compass Pathways | 23 COMP360: Transforming Mental Health Care Blockbuster Opportunity1 Large underserved markets in TRD (4M U..S. patients) & PTSD (13M U.S. patients) Compelling Data 2 successful Ph3 TRD trials: rapid effect, durable efficacy, highly differentiated in TRD Clear Accelerated Regula
Slide 24: For more information
© Compass Pathways | 24 For more information: Stephen Schultz SVP, Investor Relations stephen.schultz@compasspathways.com +1 401-290-7324 Thank you… Q&A
Slide 25: Adverse events table (>5% incidence in 25 mg arm)
© Compass Pathways | 25 25 | © Compass Pathways PlaceboCOMP360 10 mg COMP360 25 mg(>5% Incidence in 25 mg arm) MedDRA TEAE Preferred Term N=143N=142N=296 n (%) n (%) 124 (86.7)132 (93.0)280 (94.6)Any TEAE 18 (12.6)50 (35.2)133 (44.9)Nausea 49 (34.3)53 (37.3)118 (39.9)Headache 29 (20.3)38 (26.8)83 (2